Cover Image
市場調查報告書

Frontier Pharma:糖尿病併發症 - 創新性多種多樣的神經病變、腎臟病、視網膜症開發平台

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

出版商 GBI Research 商品編碼 363980
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:糖尿病併發症 - 創新性多種多樣的神經病變、腎臟病、視網膜症開發平台 Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies
出版日期: 2016年06月01日 內容資訊: 英文 73 Pages
簡介

糖尿病併發症開發平台,是含現在市場上未使用的一連串標的,由429項產品構成。分子標靶多樣性的增加,意味著糖尿病併發症的市場變化與改善的可能性高。

本報告提供糖尿病併發症市場相關調查分析,革新案例,臨床、商業性情形,開發中產品的評估,計劃評估,最近的交易等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標靶多樣化
  • 創新的First-in-Class產品 (劃時代的醫藥品)的開發現在也富有魅力
  • 法規、償付政策對First-in-Class產品的革新有利
  • 持續性的革新
  • 報告指南

第4章 臨床、商業性情形

  • 糖尿病概要
  • 糖尿病神經病變
    • 疾病概要
    • 徵兆與症狀
    • 免疫學與病因
    • 病理生理學
    • 診斷和分期
    • 預後
    • 治療的選項
  • 糖尿病腎病變
    • 疾病概要
    • 徵兆與症狀
    • 免疫學與病因
    • 病理生理學
    • 診斷和分期
    • 預後
    • 治療的選項
  • 糖尿病視網膜病變
    • 疾病概要
    • 徵兆與症狀
    • 免疫學與病因
    • 病理生理學
    • 診斷和分期
    • 預後
    • 治療的選項
  • 糖尿病併發症的上市產品概要
    • 糖尿病神經病變的上市產品概要
    • 糖尿病腎病變的上市產品概要
    • 糖尿病視網膜病變的上市產品概要

第5章 開發中產品革新的評估

  • 糖尿病神經病變:各分子類型,階段,治療標靶
  • 糖尿病腎病變:各分子類型,階段,治療標靶
  • 糖尿病視網膜病變:各分子類型,階段,治療標靶

第6章 信號 (信號傳達) 網路,疾病的因果關係,革新的調整

  • 代謝異常的信號網路的複雜
  • First-in-Class矩陣的評估

第7章 First-in-Class標的評估

第8章 交易與策略性整合

  • 產業整體First-in-Class交易
  • 授權交易
  • 共同開發交易
  • 不參予授權/共同開發交易的First-in-Class計劃

第9章 附錄

圖表

目錄
Product Code: GBIHC397MR

Executive Summary

Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence - it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.

The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.

The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-systemic conditions, as the market is currently predominantly composed of therapies that symptomatically treat the condition, or at best slow disease progression. However, as the understanding of disease pathophysiology in both diabetes and its complications increases, new targets are being identified and converted into improved therapeutic options that are better aligned with the underlying disease pathophysiology than their predecessors.

The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market. One innovative therapy is CBX-129801, a promising synthetic peptide that is currently in development for diabetic neuropathy. Innovation can also be seen within diabetic retinopathy, with therapies such as BCN070660, a topical ophthalmologic formulation currently in development.

Scope

  • What effect do current market therapies have on disease progression?
  • Which drug classes dominate the current market?
  • What additional benefits have newly approved therapies brought to the market?
  • Can the increasing number of peptides in the pipeline prove useful in diabetic neuropathy?
  • Can neuroprotective therapies prove an important addition in diabetic retinopathies?
  • Can the diverse range of molecule types and molecular targets within the pipeline help reverse disease progression?
  • To what degree is the pipeline penetrated by first-in-class innovation?
  • What is the clinical potential of first-in-class products, based on their alignment to disease-causing pathways?
  • Which are the most promising first-in-class targets in early-stage development?
  • Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons to buy

  • Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
  • Visualize the composition of the market for each diabetic complication individually, in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the pipeline for each diabetic complication individually and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking more innovative approaches to treating diabetic complications.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Identify commercial opportunities in the diabetic complications deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of diabetic complications therapies that are not yet involved in deals, and may be potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Significant Unmet Needs in Diabetic Complications Market
  • 2.2. High Proportion of First-in-Class Innovation Offers Promise in Diabetic Complications
  • 2.3. Deal Activity Varies with First-in-Class Status

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Development Remains Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Diabetes Mellitus Overview
  • 4.2. Diabetic Neuropathies
    • 4.2.1. Disease Overview
    • 4.2.2. Signs and Symptoms
    • 4.2.3. Epidemiology and Etiology
    • 4.2.4. Pathophysiology
    • 4.2.5. Diagnosis and Staging
    • 4.2.6. Prognosis
    • 4.2.7. Treatment Options
  • 4.3. Diabetic Nephropathy
    • 4.3.1. Disease Overview
    • 4.3.2. Sign and Symptoms
    • 4.3.3. Epidemiology and Etiology
    • 4.3.4. Pathophysiology
    • 4.3.5. Diagnosis and Staging
    • 4.3.6. Prognosis
    • 4.3.7. Treatment Options
  • 4.4. Diabetic Retinopathies
    • 4.4.1. Disease Overview
    • 4.4.2. Signs and Symptoms
    • 4.4.3. Epidemiology and Etiology
    • 4.4.4. Pathophysiology
    • 4.4.5. Diagnosis and Staging
    • 4.4.6. Prognosis
    • 4.4.7. Treatment Options
  • 4.5. Overview of Marketed Products in Diabetic Complications
    • 4.5.1. Overview of Marketed Products in Diabetic Neuropathies
    • 4.5.2. Overview of Marketed Products in Diabetic Nephropathy
    • 4.5.3. Overview of Marketed Products in Diabetic Retinopathies

5. Assessment of Pipeline Product Innovation

  • 5.1. Diabetic Neuropathies by Molecule Type, Phase and Therapeutic Target
    • 5.1.1. Comparative Distribution of Programs between Diabetic Neuropathy Market and Pipeline by Therapeutic Target Family
    • 5.1.2. First-in-Class Pipeline Programs Targeting Novel Molecular Targets
  • 5.2. Diabetic Nephropathy by Molecule Type, Phase and Therapeutic Target
    • 5.2.1. Comparative Distribution of Programs between the Diabetic Nephropathy Market and Pipeline by Therapeutic Target Family
    • 5.2.2. First-in-Class Pipeline Programs Targeting Novel Molecular Targets
  • 5.3. Diabetic Retinopathies by Molecule Type, Phase and Therapeutic Target
    • 5.3.1. Comparative Distribution of Programs between the Diabetic Retinopathy Market and Pipeline by Therapeutic Target Family
    • 5.3.2. First-in-Class Pipeline Programs Targeting Novel Molecular Targets
    • 5.3.3. Pipeline Products in Diabetic Complications

6. Signaling Network, Disease Causation and Innovation Alignment

  • 6.1. Complexity of Signaling Networks in Metabolic Disorders
  • 6.2. First-in-Class Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting NADPH Oxidase
  • 7.2. Pipeline Programs Targeting Glutamate Decarboxylase
  • 7.3. Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type
  • 7.4. Pipeline Programs Targeting Motilin Receptor
  • 7.5. Pipeline Programs Targeting Lysophosphatidic Acid Receptor
  • 7.6. Pipeline Programs Targeting Leukotriene B4 Receptor
  • 7.7. Pipeline Programs Targeting Integrin Alpha V
  • 7.8. Pipeline Programs Targeting Signal Transducer and Activator of Transcription

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
    • 8.2.1. Licensing Deals by Molecule Type
    • 8.2.2. Licensing Deals by Molecular Target
  • 8.3. Co-development Deals
    • 8.3.1. Co-development Deals by Molecule Type
    • 8.3.2. Co-development Deals by Molecular Target
  • 8.4. First-in-Class Programs Not Involved in Licensing or Co-development Deals

9. Appendix

  • 9.1. References
  • 9.2. Abbreviations
  • 9.3. Research Methodology
  • 9.4. Secondary Research
    • 9.4.1. Market Analysis
    • 9.4.2. Pipeline Analysis
    • 9.4.3. First-in-Class Matrix Assessment
    • 9.4.4. First-in-Class Target Profiles
    • 9.4.5. Licensing and Co-Development Deals
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Natural Development of Diabetic Nephropathy
  • Table 2: Diabetic Complications, Global, Data for NADPH Oxidase 4 as Therapeutic Target,
  • Table 3: Diabetic Complications, Global, Data for Glutamate Decarboxylase as Therapeutic Target,
  • Table 4: Diabetic Complications, Global, Data for Growth Hormone Secretagogue Receptor Type 1 as Therapeutic Target,
  • Table 5: Diabetic Complications, Global, Data for Motilin Receptor as Therapeutic Target,
  • Table 6: Diabetic Complications, Global, Data for Lysophosphatidic Acid Receptor 1 as Therapeutic Target,
  • Table 7: Diabetic Complications, Global, Data for Leukotriene B4 Receptor 1 as Therapeutic Target,
  • Table 8: Diabetic Complications, Global, Data for Integrin Alpha V as Therapeutic Target,
  • Table 9: Diabetic Complications, Global, Data for Signal Transducer and Activator of Transcription 4 as Therapeutic Target,
  • Table 10: Abbreviations

List of Figures

  • Figure 1: Diabetic Complications, Global, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals (%), 1987-
  • Figure 2: Global, Sales Performance of First-in-Class and Non-First-in-Class Products after Marketing Approval ($m),
  • Figure3: Diabetic Neuropathies, Global, Overview of Marketed Products,
  • Figure 4: Diabetic Nephropathy, Global, Overview of Marketed Products,
  • Figure 5: Diabetic Retinopathies, Global, Overview of Marketed Products,
  • Figure 6: Diabetic Neuropathies, Global, Overview of Pipeline Products,
  • Figure 7: Diabetic Neuropathies, Global, Molecular Targets in Pipeline,
  • Figure 8: Diabetic Neuropathies, Global, Pipeline by Molecular Targets and Stage of Development,
  • Figure 9: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline and Marketed Products,
  • Figure 10: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets,
  • Figure 11: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%),
  • Figure 12: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%),
  • Figure 13: Diabetic Nephropathy, Global, Overview of Pipeline Products,
  • Figure 14: Diabetic Nephropathy, Global, Molecular Targets in Pipeline,
  • Figure 15: Diabetic Nephropathy, Global, Pipeline by Molecular Targets and Stage of Development,
  • Figure 16: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline and Marketed Products,
  • Figure 17: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets,
  • Figure 18: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%),
  • Figure 19: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%),
  • Figure 20: Diabetic Retinopathies, Global, Overview of Pipeline Products,
  • Figure 21: Diabetic Retinopathies, Global, Molecular Targets in Pipeline,
  • Figure 22: Diabetic Retinopathies, Global, Pipeline by Molecular Targets and Stage of Development,
  • Figure 23: Diabetic Retinopathies, Global, Complications, Molecular Target Family Comparison, Pipeline and Marketed Products,
  • Figure 24: Diabetic Retinopathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets,
  • Figure 25: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%),
  • Figure 26: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%),
  • Figure 27: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 1),
  • Figure 28: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 2),
  • Figure 29: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 3),
  • Figure 30: Diabetic Complications, Global, Gastric Cancer, Target Matrix,
  • Figure 31: Diabetic Complications, Global, Pipeline Programs Targeting NADPH Oxidase 4,
  • Figure 32: Diabetic Complications, Global, Pipeline Programs Targeting Glutamate Decarboxylase,
  • Figure 33: Diabetic Complications, Global, Pipeline Programs Targeting Growth Hormone Secretagogue Receptor Type 1,
  • Figure 34: Diabetic Complications, Global, Pipeline Programs Targeting Motilin Receptor,
  • Figure 35: Diabetic Complications, Global, Pipeline Programs Targeting Lysophosphatidic Acid Receptor 1,
  • Figure 36: Diabetic Complications, Global, Pipeline Programs Targeting Leukotriene B4 Receptor 1,
  • Figure 37: Diabetic Complications, Global, Pipeline Programs Targeting Integrin Alpha V,
  • Figure 38: Diabetic Complications, Global, Pipeline Programs Targeting Signal Transducer and Activator of Transcription 4,
  • Figure 39: Diabetic Complications, Global, Deals by Stage of Development, 2006-
  • Figure 40: Diabetic Complications, Global, Licensing Deal Values by Stage of Development ($m), 2006-
  • Figure 41: Diabetic Complications, Global, Licensing Deal Value, 2006-
  • Figure 42: Diabetic Complications, Global, Licensing Deals by Year, 2006-
  • Figure 43: Diabetic Complications, Global, Licensing Deals by Stage of Development, 2006-
  • Figure 44: Diabetic Complications, Global, Licensing Deal Value by Stage of Development and Molecule Type, 2006-
  • Figure 45: Diabetic Complications, Global, Licensing Deal Value by Molecular Target, 2006-
  • Figure 46: Diabetic Complications, Global, Summary of Licensing Deals, 2006-
  • Figure 47: Diabetic Complications, Global, Co-development Deal Value, 2006-
  • Figure 48: Diabetic Complications, Global, Co-development Deals, 2006-
  • Figure 49: Diabetic Complications, Global, Co-development Deals by Stage of Development, 2006-
  • Figure 50: Diabetic Complications, Global, Co-development by Stage of Development and Molecule Type, 2006-
  • Figure 51: Diabetic Complications, Global, Co-development by Stage of Development and Molecular Target, 2006-
  • Figure 52: Diabetic Complications, Global, Summary of Co-development Deals, 2006-
  • Figure 53: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 1),
  • Figure 54: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 2),
  • Figure 55: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 3),
Back to Top